Greater utility of molecular subtype rather than epithelial‐to‐mesenchymal transition (EMT) markers for prognosis in high‐risk non‐muscle‐invasive (HGT1) bladder cancer

Autor: Edward C Ottley, Robert Pell, Benedict Brazier, Julianne Hollidge, Christiana Kartsonaki, Lisa Browning, Eric O'Neill, Anne E Kiltie

Publikováno v: The Journal of Pathology: Clinical Research, Vol 6, Iss 4, Pp 238-251 (2020)

Abstract Approximately 75% of bladder cancers are non‐muscle invasive (NMIBC). Of these, up to 53% of cases progress to life‐threatening muscle‐invasive bladder cancer (MIBC). Patients with high‐grade stage T1 (HGT1) NMIBC frequently undergo

Externí odkaz: https://doaj.org/article/63751b5357d0404a90b79fbc7bbc3d86

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Autor: Steven Kennish, Guenter Schmidt, Julianne Hollidge, Adrian V. S. Hill, Susan Morgan, Richard Harrop, Federica Cappuccini, Emily Pollock, Freddie C. Hamdy, Tom Evans, Andrew Protheroe, Ruth MacPherson, Pedro J Romero, James W.F. Catto, Andrea Baines, Armin Meier, L. Carter, Clare Verrill, Selena Vigano, Megan Baker, Richard J. Bryant, Irina Redchenko, Celia Mitton, Ian D. Poulton

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 8, no. 1, pp. e000928

BackgroundProstate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for the last two decades leading to a licensure of the first therapeutic cancer vaccine, Sipuleucel-T, in 201

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97785948ef8400f1f4cce8a7ab6417fb
https://jitc.bmj.com/content/8/1/e000928.full

Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial

Autor: Ruth MacPherson, Guenter Schmidt, Richard J. Bryant, James W.F. Catto, Armin Meier, Adrian V. S. Hill, L. Carter, Susan Morgan, Megan Baker, Federica Cappuccini, Clare Verrill, Steven Kennish, Selena Vigano, Emily Pollock, Pedro Romero, Julianne Hollidge, Andrew Protheroe, Richard Harrop, Freddie C. Hamdy, Ian D. Poulton, Irina Redchenko, Celia Mitton, Andrea Baines, Tom Evans

Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for a decade. However, neither of the two clinically most developed prostate cancer vaccines, Sipuleucel-T and ProstVac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67eb468d2c3219e40668ef3011daef8b
https://doi.org/10.1101/2020.03.05.20031500